Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 1 h ago

TENAX THERAPEUTICS, INC.: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Biotechnology Value Fund L.P. amended its Schedule 13G stake filing for Tenax Therapeutics, Inc., disclosing the change to the SEC under accession number 0000921895-26-003191. The filing updates the fund's previously reported ownership position in the clinical-stage biotech, though the amended document did not specify a revised share count or percentage in the headline disclosure. The move matters because 13G amendments signal shifts in passive or institutional ownership that can influence Tenax's shareholder base and governance dynamics. Investors will watch for the full filing details to confirm whether Biotechnology Value Fund increased, trimmed or maintained its stake, and whether other institutional holders follow suit.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

BIOTECHNOLOGY VALUE FUND L P, TENAX THERAPEUTICS, INC.